Last Updated: 2004-01-19 10:38:41 -0400 (Reuters Health)
COPENHAGEN (Reuters) - Denmark's biotech firm Pharmexa on Monday announced positive results from first clinical tests of its breast cancer vaccine.
"The data show that the vaccine is safe and that it induces HER-2 specific antibodies," the company said in a statement.
With the results from the study of its HER-2 Protein AutoVac vaccine on 10 breast cancer patients in the United States, Pharmexa said it plans to continue the vaccine development during the second half of 2004 with phase II trials.
Depending on the speed of patient enrollment, Pharmexa expects results from the next study by mid-2006.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home